Military makes progress on dengue jab

Military scientists have been hard at work in Thailand developing a new vaccine to combat dengue fever. For the U.S. military, the prime motivation is protecting the troops from a disease that has afflicted American soldiers as recently as the ‘90s. But if they're successful in getting a new vaccine that can be commercialized by the middle of the next decade, they'll also save people from a disease that hospitalizes half a million a year.

"All we care about is that we get a vaccine that protects soldiers," Lt. Col. Stephen J. Thomas, a medical doctor who is director of dengue vaccine development in the Bangkok laboratory, told the New York Times, "Fortunately a lot of our concerns are also global health concerns."

And just down the street from the military's lab, Sanofi-Aventis and a local university are working on a separate vaccine that also has raised hopes of near-term vaccine.

"We're further along with the dengue vaccine than we've ever been," said Duane J. Gubler, director of the emerging infectious diseases department of the Duke-N.U.S. Graduate Medical School in Singapore. "There's a good possibility that we'll have a vaccine in five to seven years."

- read the article in the New York Times

ALSO: Vical said that that the Naval Medical Research Center plans to conduct preclinical and Phase I evaluation of a dengue DNA vaccine formulated with the company's Vaxfectin adjuvant and delivered with the Biojector 2000 needle-free injection system. Release

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.